AstraZeneca has revealed a genetics research programme which will seek to develop a new range of drugs targeted at a range of diseases.
Drawing on the Innovative Genomics Initiative (University of California Berkeley and UC San Francisco) and the Broad Institute (Harvard University and Massachusetts Institute of Technology), the pharmaceutical giant will be utilising genetic scissors to “snip out” genes that cause diseases such as cancer and diabetes, and then develop drugs to target the conditions.
Based on research conducted…
